Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is studying EIK1004 (also called IMP1707) in patients with advanced solid tumors. The study focuses on specific types of cancers, including endometrioid ovarian cancer, fallopian tube cancer, primary peritoneal cancer, HER2-negative breast cancer, metastatic castration-resistant prostate cancer, and metastatic pancreatic ductal adenocarcinoma. The purpose is to evaluate the safety, tolerability, and activity of EIK1004 when given as a single medication (monotherapy).

The study is designed in multiple parts. Part 1 focuses on finding the maximum tolerated dose or maximum administered dose and the recommended dose for further evaluation. Part 2 continues to assess safety and tolerability at the established dose. Participants must have specific genetic mutations in genes such as BRCA1, BRCA2, PALB2, RAD51B, RAD51C, or RAD51D. These are genes involved in DNA repair, and mutations in these genes may make cancer cells more susceptible to certain treatments.

The trial is "open-label," which means both doctors and patients know which treatment is being given. Patients will receive the medication orally (by mouth) and will be monitored for side effects and response to treatment. Some patients with brain metastases (cancer that has spread to the brain) may also be eligible to participate under specific conditions.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study Start

    After qualifying for the study and completing screening procedures, you will begin participation in this clinical trial for EIK1004, a medication being tested for advanced solid tumors.

    This study has two parts: Part 1 focuses on finding the right dose, and Part 2 examines how well that dose works. Your participation will be in either Part 1 or Part 2, depending on when you join the study.

  2. Step 2

    Medication Administration

    You will take EIK1004 tablets by mouth. The tablets come in 5mg and 20mg strengths.

    In Part 1 (dose-finding), different participants may receive different doses to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended dose for expansion (RDE).

    The exact dosage and schedule will be provided by your study doctor, who will monitor your response to the medication throughout the trial.

  3. Step 3

    Safety Monitoring

    Throughout the study, you will have regular medical appointments to monitor how your body responds to EIK1004.

    Your study team will track any side effects, which are called adverse events (AEs). They will pay special attention to dose-limiting toxicities (DLTs), which are side effects that might require changing your dose.

    Blood samples will be collected to measure the amount of EIK1004 in your body after single and multiple doses. This is called pharmacokinetics (PK) testing.

  4. Step 4

    Effectiveness Monitoring

    You will have regular imaging scans to check if your tumors are responding to treatment.

    The study team will measure several aspects of your response:

    • Objective Response: Whether your tumors shrink

    • Disease Control: Whether your cancer stays stable or improves

    • Duration of Response: How long any improvement lasts

    • Time to Response: How quickly your cancer responds to treatment

    If you have brain metastases (cancer that has spread to the brain), the team will also track the Time to CNS progression, which measures how long it takes before cancer in the central nervous system worsens.

  5. Step 5

    Ongoing Treatment

    You will continue taking EIK1004 as long as you are benefiting from treatment and not experiencing unacceptable side effects.

    If you were receiving hormone therapy (such as ADT for prostate cancer) before starting the study, you will continue this treatment during the study.

    Throughout your participation, your study doctor will closely monitor your condition and may adjust your treatment as needed.

  6. Step 6

    Study Completion

    Your participation will end if your disease progresses, you experience unacceptable side effects, you decide to withdraw, or the study ends.

    The entire study is expected to run until July 2027, though individual participation length will vary based on your response to treatment.

    After your last dose of the study medication, you may have follow-up visits to check your health status.

Who can join the trial?

18 criteria

  • You must volunteer to participate and follow all study procedures.
  • You must be at least 18 years old.
  • You must have one of these cancer types:
    • Advanced, recurrent, or metastatic (spread to other parts of the body) endometrioid ovarian, fallopian tube, or primary peritoneal cancer with at least 1 prior chemotherapy
    • Advanced, recurrent, or metastatic HER2-negative breast cancer with at least 1 prior chemotherapy
    • Metastatic castration-resistant prostate cancer (mCRPC) with ongoing hormone therapy
    • Advanced, recurrent, or metastatic pancreatic cancer with prior treatment
    • You must have mutations (changes in DNA) in one of these genes: BRCA1, BRCA2, PALB2, RAD51B, RAD51C or RAD51D.
    • You must have cancer that has been shown to be growing (progressing) on scans.
    • For prostate cancer patients, increasing PSA levels (a blood test that can indicate prostate cancer activity) is acceptable.
    • You must have an ECOG Performance Status of 0 to 1 (able to perform daily activities with minimal or no assistance).
    • Your life expectancy must be at least 12 weeks.
    • You must have adequate organ function.
    • Female participants must either:
      • Be unable to have children, or
      • Be post-menopausal (no longer having menstrual periods), or
      • Have a negative pregnancy test and use effective birth control if able to become pregnant
      • Male participants must have had a vasectomy or use effective birth control methods from the start of the study until 6 months after the last dose.
      • For patients previously treated with PARP inhibitors (a type of cancer drug), up to 1 prior treatment is allowed (Part 1 only).
      • If you have cancer that has spread to the brain (CNS metastases), you must meet specific requirements about your brain lesions and their treatment.

Who cannot join the trial?

10 criteria

  • Having received another anti-cancer therapy within 28 days before starting the study treatment.
  • Having had major surgery within 28 days before the first dose of the study drug.
  • Having active or untreated brain metastases (cancer that has spread to the brain).
  • Having received a live vaccine within 30 days before starting the study treatment.
  • Having a history of allergic reactions to similar drugs.
  • Having an active infection requiring treatment.
  • Being pregnant or breastfeeding.
  • Having unstable heart disease.
  • Having been diagnosed with another cancer within the past 3 years (except for certain skin cancers or cancers considered cured).
  • Having serious uncontrolled medical disorders that could affect your participation in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

EIK1004 (IMP1707) is an investigational medication being studied for the treatment of advanced solid tumors. It is administered as a monotherapy, which means it is given alone without other cancer treatments. The study aims to find the appropriate dosage that is both safe and potentially effective for patients with advanced solid tumors.

What is already known about the treatment

EIK1004 (IMP1707) – An investigational medication currently being studied in clinical trials for advanced solid tumors. It is administered as a monotherapy (used alone rather than in combination with other drugs) with specific dosing being evaluated in the ongoing trials. While the exact mechanism of action at the molecular level is not fully disclosed in the provided information, researchers are assessing its safety, tolerability, and activity against various advanced solid tumors. The clinical trial is being conducted in phases (1/2) to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended dose for expansion (RDE), suggesting this medication is still in early development stages for potential cancer treatment.

Investigated diseases

Advanced solid tumors – A term referring to cancers that have formed a solid mass of cells and have progressed to an advanced stage. These tumors originate in various tissues and organs throughout the body, such as the breast, lung, colon, prostate, or pancreas. In advanced stages, the cancer has typically grown larger in its original location and may have spread (metastasized) to nearby tissues, lymph nodes, or distant parts of the body. Advanced solid tumors are characterized by abnormal cell growth that continues uncontrollably, eventually interfering with normal bodily functions. The specific symptoms vary widely depending on the tumor's location and extent of spread.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-520395-99-00Protocol codeEIK1004-001Estimated enrolment51 patientsSponsorEikon Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.